| Sponsor |
Protocol Code |
Trial Name |
Principal Investigator |
Phase |
Therapeutic Area |
Diseases and Conditions |
| RS Research |
RS-0139 |
A multicenter, open-label, two-step, phase Ia/Ib study of tumor-targeted prodrug RS 0139 in patients with recurrent, locally advanced and/or metastatic solid tumors |
HAKAN ORER (Prof.Dr.) |
Phase 1a/1b |
Oncology |
Cancer |
| AstraZeneca |
Mono-Ola1- |
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1) |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Ovarian Cancer |
| AstraZeneca |
D926FC00001 |
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab
Deruxtecan (Dato-DXd) in Combination with Immunotherapy with or without Carboplatin in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) |
PERRAN FULDEN YUMUK (Prof.Dr.) |
Phase 1b |
Oncology |
Lung Cancer |
inTUMO Therapeutics, Inc. |
INTUMO-002 |
A study to evaluate the safety and performance of Ionic Liquid on liver tumors in patients requiring tumor ablation
A prospective, single-arm, single-center clinical trial |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Medical Device |
Oncology |
Liver Cancer |
| Regeneron Pharmaceuticals, Inc. |
R3767-ONC-2235 |
A Randomized, double blind Phase 2/3 study of Fianlimab (Anti-Lag-3 Antibody) in combination with Cemiplimab (Anti-PD-1 Antibody) versus Cemiplimab monotherapy in first-line treatment of patients with advanced non small cell lung cancer(NSCLC) WİTH TUMORS EXPRESSİNG PD-L1 ≥50% |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT116-01 |
LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 1 |
Oncology |
Lung Cancer |
| GSK |
221530 |
A randomized, double-blind, placebo-controlled phase 3 study to evaluate dostarlimab as sequential therapy after chemoradiation in participants with locally advanced unresected head and neck squamous cell carcinoma. |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase3 |
Oncology |
Head and Neck Cancer |
| Johnson and Johnson |
56021927PCR3015 |
Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort |
DENİZ TURAL (Prof.Dr.) |
Phase 2 |
Oncology |
Prostate Cancer |
| BioNTech SE |
BNT327-01 |
A Phase II, multi-site, open-label, parallel group trial of BNT327 in combination with chemotherapy for participants with untreated extensive-stage small-cell lung cancer and participants with previously treated small-cell lung cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT327-02 |
A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Breast Cancer |
| Amgen |
AMGEN 20230298 |
A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of subcutaneous tarlatamab in subjects with extensive stage small cell lung cancer (DeLLphi-308). |
PERRAN FULDEN YUMUK (Prof.Dr.) |
Phase 1b |
Oncology |
Lung Cancer |
| OncoC4 Inc. |
PRESERVE-003 |
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors. |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| Merck Sharp & Dohme LLC |
V940-005 |
Phase 2, randomized, double-blind, placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with high-risk muscle-invasive urothelial carcinoma post-radical resection. |
DENİZ TURAL (Prof.Dr.) |
Phase 2 |
Oncology |
Bladder Cancer |
| Merck Sharp & Dohme LLC |
MK-5684-004 |
A phase 3, randomized, open-label study of MK-5684 versus alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) that progressed on or after prior treatment with one next-generation hormonal agent (NHA). |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| Pfizer Inc. |
C2321003 |
A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (Mevrometostat) With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (MEVPRO-2) |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| GSK |
223559 |
A phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors. |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 1 |
Oncology |
Cancer |
| BioNTech SE |
BNT327-03 |
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with firstline extensive-stage small-cell lung cance |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT327-06 |
A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2/3 |
Oncology |
Lung Cancer |
| Pfizer Inc. |
C2321014 |
A phase 3, randomized, open-label study of pf-06821497 (mevrometostat) in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously treated with abiraterone acetate (MEVPRO-1) |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| Merck Sharp & Dohme LLC |
MK-3120-002 |
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of
MK-3120 in Participants with Advanced Solid Tumors |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 1 |
Oncology |
Cancer |
| GSK |
223674 |
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| AstraZeneca |
D702AC00001 |
A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2 positive Gastric Cancer
(ARTEMIDE-Gastric01) |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Gastric Cancer |
| BioNTech SE |
BNT327-07 |
A Phase II, multisite, open-label, single arm trial of BNT327 in combination with docetaxel in second-line stage IV non-small cell lung cancer (NSCLC) following chemoimmunotherapy |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| MSD |
MK-1022-016-01 |
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptorpositive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Breast Cancer |
| Johnson and Johnson |
61186372PANSC2004 |
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 1/2 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT326-02 |
A Phase Ib/II, multi-site, open-label, dose finding trial to evaluate the safety,
efficacy, and pharmacokinetics of BNT326 in combination with BNT327 in
participants with advanced non-small cell lung cancer (NSCLC). |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| AstraZeneca |
D7630C00001 |
Phase III, Open-label, Randomised Study of Datopotamab
Deruxtecan (Dato-DXd) With or Without Durvalumab Compared
with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination
With Pembrolizumab in Patients with PD-L1 Positive Locally
Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
(TROPION-Breast05) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Breast Cancer |
| Johnson and Johnson |
78278343PCR3003 |
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirectingAgent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for MetastaticCastration-resistant Prostate Cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| BioNTech SE |
BNT324-01 |
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 1 |
Oncology |
Lung Cancer |
| MSD |
MK5684-015 |
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants
With Selected Solid Tumors |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Cancer |
| Qilu Pharmaceutical Co., Ltd. |
Qilu QL2107-102 |
A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence
Clinical Trial of QL2107 (Keytruda® Biosimilar Candidate) in Comparison with
Keytruda® (Pembrolizumab) for Adjuvant Therapy to Demonstrate
Pharmacokinetic Similarity in Subjects with Resected Non-Small Cell Lung
Cancer |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT323-03 |
A Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Breast Cancer |
| AstraZeneca |
D9727C00001 |
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02 |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| Merck Sharp & Dohme LLC |
MK1084-014 |
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Cancer |
| Merck Sharp & Dohme LLC |
MK-2400-01A-01 |
A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02) |
DENİZ TURAL (Prof.Dr.) |
Phase 2 |
Oncology |
Prostate Cancer |
| Merus N.V. |
MCLA-158-CL03 |
A Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Head and Neck Cancer |
| MSD |
V940-013 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in
Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| Merck Sharp & Dohme LLC |
MK3475-01J |
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| AstraZeneca |
D702NC00001 |
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02) |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase 3 |
Oncology |
Biliary Tract Cancer |